Our History

Since 2001, Abzena has transformed itself into a renowned, global complex biologics and bioconjugates development and manufacturing accelerator. We work with you, our clients, to de-risk and streamline the development and manufacture of novel treatments. Together, we can medicines to patients, faster.

We are proud of our heritage. What really excites us today is the future of next-generation medicine built on our clients incredible ideas. We are ready to help you find solutions for unmet clinical needs through our extensive capabilities, integrated locations, and our values of Scientific Innovation, Integrity and Quality. Access our corporate brochure to find out what truly sets Abzena apart from other suppliers.

Take a look at some of our significant milestones that have shaped our journey to become a trusted, strategic partner to the global pharmaceutical and biotech industry.



Abzena was established in 2013 when two companies, PolyTherics and Antitope, were combined to create a single leading provider of technologies and services to enable better biopharmaceuticals.

Located in the UK, PolyTherics was founded in 2001, and was viewed as an innovator in the bioconjugate space. The company specialized in proprietary site-specific conjugation technologies for antibody drug conjugate development and solutions for optimization of the therapeutic properties of biopharmaceuticals. They were the creators of Abzena's unique ThioBridge® conjugation technology platform, which has been proven to enhance the development of antibody drug conjugates (ADCs) by overcoming challenges and improving stability, potency and efficacy.

Also located in the UK, Antitope, founded in 2004, was considered to be an industry leader in immunogenicity assessment, protein engineering to create humanized antibodies and deimmunized therapeutic proteins and cell line development for manufacture. They were the creators of EpiScreen, a robust ex-vivo immunogenicity assessment platform and Composite Human Antibody and Composite Protein platforms, which reduce immunogenicity risk and confidently move antibodies and complex biologics forward into development.

Together they served a global customer base including the top multinational large pharmaceutical groups to emerging biotechs.


Abzena expanded its footprint into the US with the acquisition of PacificGMP in 2015. This expansion enabled Abzena to expand its services and provide broader support for its customers’ development projects, by offering biopharmaceutical manufacturing services.

Located in San Diego, CA, PacificGMP, was founded in 2005 and was considered to be a pioneer in single-use manufacturing technology, which is increasingly being used to manufacture biopharmaceuticals. The sites services include process and analytical development, non-GMP and cGMP manufacturing, and regulatory support.


Our US footprint and services toolkit grew with the acquisition of The Chemistry Research Solution (TCRS) in 2016. Located in Bristol, PA, TCRS was founded in 2012 with a focus on producing and analyzing antibody drug conjugates (ADCs). This acquisition broadened Abzena's capabilities in the development and GMP manufacture of ADCs, providing customers a fully integrated offering from discovery through development and manufacture under a single organization.


Welsh Carson Anderson & Stowe (WCAS), one of the world’s leading private equity investors, purchased Abzena in 2018. At this time the company was comprised of three locations including Cambridge, UK, Bristol PA, USA and San Diego CA, USA.


Since the acquisition, WCAS has significantly invested in late phase and commercial cGMP manufacturing facilities in San Diego, CA and Bristol, PA.